Article Text

PDF
Microsimulation and clinical outcomes analysis support a lower age threshold for use of biological valves
  1. Serban Stoica1,
  2. Kimberley Goldsmith2,
  3. Nikolaos Demiris2,
  4. Prakash Punjabi3,
  5. Geoffrey Berg4,
  6. Linda Sharples2,
  7. Stephen Large5
  1. 1Bristol Royal Children's Hospital, Bristol, UK
  2. 2Medical Research Council Biostatistics Unit, Cambridge, UK
  3. 3Hammersmith Hospital, London, UK
  4. 4Golden Jubilee National Hospital, Glasgow, UK
  5. 5Papworth Hospital, Cambridge, UK
  1. Correspondence to Stephen Large, Papworth Hospital, Cambridge CB3 8RE, UK; stephen.large{at}papworth.nhs.uk

Abstract

Objective To characterise contemporary results of aortic valve replacement in relation to type of prosthesis and subsequent competing hazards.

Methods 5470 procedures in 5433 consecutive patients with aortic valve replacement ± coronary artery bypass grafting (CABG) were studied. Microsimulation of survival and valve-related outcomes was performed based on meta-analysis and patient data inputs, with separate models for age, gender and CABG. Survival was validated against the UK Heart Valve Registry.

Results Patient survival at 1, 5 and 10 years was 90%, 78% and 57%, respectively. The crossover points at which bioprostheses and mechanical prostheses conferred similar life expectancy (LE) was 59 years for men and women (no significant difference between prosthesis types between the ages of 56 and 69 for men, and 58 an 63 for women). The improvement in event-free LE for mechanical valves was greater at younger ages with a crossover point of 66 years for men and 67 years for women. Long-term survival was independently influenced by age, male gender and concomitant CABG, but not by type of prosthesis. In bioprostheses the most common long-term occurrence was structural deterioration. For men aged 55, 65 and 75 at initial operation it had a lifetime incidence of 50%, 30% and 13%, respectively. The simulation output showed excellent agreement with registry data.

Conclusion Bioprostheses can be implanted selectively in patients as young as 56 without significant adverse effects on life expectancy, although event-free life expectancy remains significantly lower with bioprostheses up to age of implant of 63.

  • Aortic valve, replacement
  • heart valve, bioprostheses
  • heart valve, mechanical
  • surgery-valve
  • aortic valve disease

Statistics from Altmetric.com

Footnotes

  • Linked articles 207050.

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles